Association of Epicardial Adipose Tissue and High-Risk Plaque Characteristics: A Systematic Review and Meta-Analysis
Overview
Authors
Affiliations
Background: Epicardial adipose tissue (EAT) is hypothesized to alter atherosclerotic plaque composition, with potential development of high-risk plaque (HRP). EAT can be measured by volumetric assessment (EAT-v) or linear thickness (EAT-t). We performed a systematic review and random-effects meta-analysis to assess the association of EAT with HRP and whether this association is dependent on the measurement method used.
Methods And Results: Electronic databases were systematically searched up to October 2016. Studies reporting HRP by computed tomography or intracoronary imaging and studies measuring EAT-v or EAT-t were included. Odds ratios were extracted from multivariable models reporting the association of EAT with HRP and described as pooled estimates with 95% confidence intervals (CIs). Analysis was stratified by EAT measurement method. Nine studies (n=3772 patients) were included with 7 measuring EAT-v and 2 measuring EAT-t. Increasing EAT was significantly associated with the presence of HRP (odds ratio: 1.26 [95% CI, 1.11-1.43]; <0.001). Patients with HRP had higher EAT-v than those without (weighted mean difference: 28.3 mL [95% CI, 18.8-37.8 mL]; <0.001). EAT-v was associated with HRP (odds ratio: 1.19 [95% CI, 1.06-1.33]; <0.001); however, EAT-t was not (odds ratio: 3.09 [95% CI, 0.56-17]; =0.2). Estimates remained significant when adjusted for small-study effect bias (odds ratio: 1.13 [95% CI, 1.03-1.28]; =0.04).
Conclusions: Increasing EAT is associated with the presence of HRP, and patients with HRP have higher quantified EAT-v. The association of EAT-v with HRP is significant compared with EAT-t; however, a larger scale study is still required, and further evaluation is needed to assess whether EAT may be a potential therapeutic target for novel pharmaceutical agents.
Clinical Trial Registration: URL: https://www.crd.york.ac.uk/. Unique identifier: CRD42017055473.
Molnar D, Bjornson E, Hjelmgren O, Adiels M, Backhed F, Bergstrom G Int J Cardiol Heart Vasc. 2025; 56:101613.
PMID: 39906627 PMC: 11791301. DOI: 10.1016/j.ijcha.2025.101613.
Baichoo R, Fu J, Xiong X, Zhou Q, Guan X, Xu X Quant Imaging Med Surg. 2024; 14(12):9685-9697.
PMID: 39698616 PMC: 11651924. DOI: 10.21037/qims-24-1245.
Lipomatous hypertrophy of the interatrial septum: a distinct adipose tissue type in COPD?.
Lacaita P, Kindl B, Plank F, Beyer C, Bilgeri V, Barbieri F ERJ Open Res. 2024; 10(5).
PMID: 39319042 PMC: 11417605. DOI: 10.1183/23120541.00295-2024.
Filtz A, Lorenzatti D, Scotti A, Pina P, Fernandez-Hazim C, Huang D Am J Prev Cardiol. 2024; 19:100711.
PMID: 39157644 PMC: 11327837. DOI: 10.1016/j.ajpc.2024.100711.
Dimitriadis K, Pyrpyris N, Theofilis P, Mantzouranis E, Beneki E, Kostakis P Diagnostics (Basel). 2024; 14(15).
PMID: 39125547 PMC: 11311283. DOI: 10.3390/diagnostics14151671.